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A R T I C L E   I N F O A B S T R A C T 
Nutraceuticals provide an additional health or medicinal benefit besides their 
nutritional value and are therefore marketed for the prevention and treatment of 
certain conditions. Nutraceuticals contain natural ingredients, usually presented in 
the form of functional foods or as dietary supplements. Many of the ingredients are 
susceptible to degradation by gastric acid or can provoke nauseatic feelings or 
induce vomiting on oral administration. Gastroresistant coatings, widely researched 
and used in pharmaceuticals, employ enteric polymers which  are not regarded as 
natural ingredients or do not possess GRAS (generally regarded as safe) status by 
the regulatory bodies, thus cannot be used for nutraceutical products. Consequently, 
most nutraceuticals are not formulated as gastroresistant and can therefore lack 
efficacy or are well tolerated. This manuscript provides a critical review of natural 
substances employed in producing gastroresistant products, their shortcomings, 
and potential industrial applications. It also identifies current gaps in our 
knowledge to encourage further research in this area. 
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INTRODUCTION 
In recent years, nutraceuticals have been widely 
adopted in the western world with a market value of 
over US$50bn in the US and US$30bn in Europe in 
2010 (Frost and Sullivan, 2010).  Innovation and new 
product development have been the focus of 
development activities with reported increases in 
research and development expenditure over recent 
years increasing the global nutraceuticals market 
value to US$165.62bn in 2014, with a predicted value 
of US$278.96bn by the end of 2021 (TMP 2015). 
Products such as dietary supplements, functional 
foods or herbal products were given the term, 
nutraceuticals (from the combination of “nutrition” 
and “pharmaceuticals”), in 1989 (Kalra, 2003). They 
are reported to provide numerous medical or health 
benefits and their therapeutic value has been 
documented as anti-fatigue, natural antioxidants and 
anti-inflammatory agents (Kuppusamy et al., 2014; 
Zaki, 2014). More significantly, it is claimed they 
have roles in the prevention or delay of several 
diseases such as arthritis (Akhtar and Haqqi, 2012), 
cancer (Kuppusamy et al., 2014; Salami et al., 2013; 
Wargovich et al., 2010), metabolic (Davi et al., 2010) 
and cardiovascular diseases (Garcia-Rios et al., 2013; 
Ramaa et al., 2006; Zuchi et al., 2010), 
neurodegenerative diseases (Mecocci et al., 2014; 
Rigacci and Stefani, 2015) and even osteoporosis 
(Nieves, 2013). However, despite these claims, no 
clinical evidence has been published so far regarding 
these products. The desired effects of these 
substances can only be achieved when the substance 
is released intact at the correct place in the 
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gastrointestinal (GI) tract. For example, some of these 
substances are susceptible to degradation by gastric 
acid or can provoke nauseatic feelings or induce 
vomiting on oral administration. Particularly, some 
probiotic-containing formulations may even need to 
pass through the small intestine to the colon in order 
to exert their effects. Therefore, in order to achieve its 
goal, the formulation has to be stable during 
residence within the challenging environment in the 
stomach.  
The design of these formulations can be very diverse 
and a plethora of materials, both natural and 
synthetic, are already described (Agyilirah and 
Banker, 1991; Hussan et al., 2012; Kendall and Basit, 
2006; Rajpurohit et al., 2010). The first attempt to 
create an enteric formulation, exploiting the 
insolubility of materials in the stomach, is attributed 
to a German physician who reported clinical case 
studies using keratin-coated carbolic acid pills, in 
1884 (Unna, 1884). A range of different approaches 
has been designed ever since in order to provide 
gastric protection to acid-labile substances, from 
tablets with enteric coatings, to emulsions intended 
to be added to food or beverages (Chen et al., 2014; 
Ron et al., 2010; Sansone et al., 2011; Semo et al., 2007; 
Shpigelman et al., 2014). The mechanisms behind 
many of these approaches exploit the significant pH 
changes across the GI tract, from very acidic in 
stomach (pH 1-2) to less acidic in the duodenum (pH 
6-7) (Ibekwe et al., 2008). 
Thus, formulations can be designed to respond to 
changes in the pH and disintegrate at the desired 
location. Polymeric coatings with carboxylic moieties 
are usually used to achieve this purpose. When in 
contact with gastrointestinal milieu at a pH higher 
that the polymer’s pKa, the ionised form of the 
polymer is predominant, thus increasing the 
solubility of the polymer, leading to the 
disintegration of the coating system and drug 
release.  
Simpler formulations have also been designed to 
delay the release of the active substance in a pH 
independent manner so that it is contained within the 
delivery system until gastric emptying, or even until 
almost complete passage through the small intestine 
(Tubic-Grozdanis et al., 2008). Although the pH in 
the stomach may vary depending on prandial state, 
intra-subject and inter-subject variability thus 
leading to inconsistency in delivery (Fallingborg et 
al., 1989; McConnell et al., 2008), the delayed-release 
approach is similarly subject to variation.  This is due 
to the fact that stomach residence time also fluctuates 
greatly, (from 30 min to 5 h) (McConnell et al., 2008), 
whereas water empties from the fasted stomach in 
times as short as 10-15 min (Ziessman et al., 2009). In 
some conditions, gastric time can be even more 
delayed (up to 10h post-dosing (Davis et al., 1984)), 
particularly in the case of single-unit dosage forms in 
the event of the dosage form having not emptied the 
stomach prior to the subsequent ingestion of a meal. 
In the fasted state, gastric motility is under the 
control of the migrating myoeletric complex (MMC), 
which helps to empty larger objects from stomach. 
However, the MMC is disrupted in the presence of 
food, contributing to longer gastric retention of 
modified release single-unit dosage forms in 
particular (Varum et al., 2010). Moreover, and even 
though the small intestine transit times are regularly 
reported as constant at 3-4 h (Davis et al., 1986), some 
studies have reported significant variability amongst 
small intestine transit times (Fallingborg et al., 1989; 
McConnell et al., 2008). These variations in transit 
times may cause the formulation to pass through the 
GI tract without completely releasing the active 
substance or, by staying in the stomach for a 
prolonged time, even prematurely releasing it in the 
stomach.  
A range of polymeric materials has been successfully 
used to prepare gastroresistant pharmaceutical 
dosage forms, with poly(meth)acrylates, (copolymer 
of methacrylic acid and either methyl-methacrylate 
or ethyl acrylate), cellulose-based materials and 
polyvinyl derivatives being most common (Cole et 
al., 2002). However, these polymers are of synthetic 
or semi-synthetic origin and cannot be used routinely 
in delivering nutritional substances needing to by-
pass the stomach. Hence, there is a need for natural 
polymers offering sufficient enteric protection for the 
nutraceutical industry. Just like other natural 
substances, these polymers are also subject to batch-
to-batch variability and to the difficulty of 
eliminating or reducing contaminants, which may 
have consequences in the performance of dosage 
forms. Despite these issues, natural polymers are 
needed to address this gap in nutraceutical market 
  https://doi.org/10.5920/bjpharm.2017.01  
Barbosa et al. (2017) BJPharm 2(1), 14-30   16 
until a desired synthetic coating is approved for 
nutraceutical use globally.  
The list of natural materials that are already listed as 
“generally regarded as safe” (GRAS) is long, and can 
be readily exploited for this application. There is a 
significant amount of research in formulating novel 
solutions for gastroresistant nutraceutical products, 
so-called traditional formulations, using natural 
polymers. This manuscript provides a critical review 
of the published literature in this area, highlighting 
shortcomings, and potential industrial applications. 
It also identifies current gaps in our knowledge to 
encourage further research in this area.  
CELLULOSE-BASED MATERIALS 
Cellulose is a polysaccharide consisting of a linear 
chain of glucose (Fig. 1) and is a constituent of most 
plant cell walls, some algae and is excreted by some 
bacteria, making it the most abundant biopolymer in 
nature (Klemm et al., 2005).  
Cellulose has been used since the 19th century in 
industrial applications such as leather, paints, 
plastics, fibres and films (Kamide, 2005). Its 
biocompatibility, biodegradability and low toxicity 
ensured its generalised use. However, due to its 
insolubility in water, several cellulose derivatives 
were produced, mainly ester and ether derivatives. 
Most of these modifications afford cellulose a greater 
solubility in water, along with different 
physicochemical and mechanical properties (Shokri 
and Adibki, 2013).  
 
Fig. 1. Chemical structure of cellulose 
In pharmaceutical industries, cellulose derivatives 
have been applied in very diverse fields such as: 
bioadhesive and mucoadhesive drug delivery 
systems, general coating processes, extended release 
dosage forms, osmotic drug delivery systems, enteric 
coated solid dosage forms, etc (Shokri and Adibki, 
2013). Cellulose derivatives are also used as enteric 
coatings in pharmaceutical applications, being 
resistant to acidic pH while becoming soluble in less 
acidic conditions. These derivatives include cellulose 
acetate phthalate (CAP), hydroxypropylmethyl 
cellulose phthalate (HPMCP) or hydroxypropyl 
methyl cellulose acetate succinate (HPMC-AS) 
(Shokri and Adibki, 2013). These polymers are 
however not considered ‘generally recognized as 
safe’ (GRAS) substances, due to their chemical 
modifications and to the lack of studies regarding 
possible side effects. For this reason their use for 
nutraceuticals is not allowed, as they may not be 
considered as food grade products.  
A commercial HPMC (hydroxypropyl methyl 
cellulose) capsule, co-formulated with gellan gum, 
has been recently marketed under the brand name 
DRCaps™, which claims to provide protection to 
acid-sensitive ingredients by a delaying-release 
mechanism  (Marzorati et al., 2015). The combination 
of HPMC and the gum forms a gel on contact with 
gastric fluids, which delays the capsule 
disintegration in anticipation of a delayed release 
until capsule is emptied in small intestine. This 
approach is however, prone to inter- and intra-
subject variability in gastric retention time, as 
mentioned earlier, hence significantly affecting its 
gastroresistant functionality. 
Due to its good film-forming properties and 
polymer-to-polymer adhesion, HPMC is sometimes 
used with other enteric materials in order to improve 
the plasticity of the main polymer or as a pre-coating 
(Cole et al., 2002). Additionally, a cellulose-based 
enteric coating, Nutrateric®, was developed by 
Colorcon® to be used for nutraceutical products. 
Nutrateric® is an ethylcellulose coating, containing 
sodium alginate as a pH-dependent pore former 
(Colorcon®, 2015). When using coating levels equal 
to, or higher than, 6.7 mg/cm2, tablets containing 
aspirin or caffeine remained intact for 2 h in 0.1M 
HCl, while disintegrating quickly (2-9 min) in 0.05M 
pH 6.8 phosphate buffer (Young et al., 2006). Sodium 
alginate dissolves at intestinal pH, hence forming 
pores in the ethylcellulose films, enabling pH 
dependent release. However, in another study 
(Merchant et al., 2009) the robustness of Nutrateric®-
coated tablets was investigated. The Nutrateric® -
coated tablets were found intact in pH 1.2 HCl after 
two hours, however swelling was noticed at pH 2.0. 
Complete disintegration of the coated tablets was 
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observed at pH 2.5 and 80% drug release was 
observed within 75 min in this medium. A further 
study by Czarnocka and Alhnan (2015) also 
confirmed the inability of Nutrateric® to withstand 
gastric conditions at pH 2.0 or higher. The basal 
gastric pH, measured in 252 healthy men and 113 
healthy women under fasted conditions, has been 
reported as pH 2.16 ± 0.09 (males) and 2.79 ± 0.18 
(females) (Feldman and Barnett, 1991). This indicates 
that Nutrateric® may result in premature drug 
release in the stomach. Although the coating was 
intact at pH ≤ 2.0, when tablets were transferred to 
pH 6.8 USP phosphate buffer, the drug release was 
very slow, with a lag time of 70 min (6% coating 
weight gain). This is in contrast to the <10 minutes 
disintegration observed by Young et al. (2006) in 
0.05M pH 6.8 phosphate buffer.  
The use of compendial phosphate buffer in 
dissolution testing as surrogate for the GI fluids is a 
dramatic oversimplification. The ionic composition 
and the buffer capacity of phosphate-based media 
are not close to the components in the intestinal 
milieu (Liu et al., 2011). For example, jejunal fluid 
contains mainly bicarbonate, chloride and calcium 
ions. However, none of these ions are present in 
phosphate buffers. Some phosphate buffered saline 
solutions contain additional ions, however their 
concentration is not comparable to those in vivo. Due 
to the similarity in ionic strength and the buffer 
capacity, mHanks buffer (predominantly buffered by 
bicarbonate ions) provides a much closer surrogate 
to jejunal fluids. Therefore, bicarbonate buffers offer 
a more suitable option to simulate intestinal 
conditions for in-vitro release assays and dissolution 
tests. In particular, a study by Liu et al. (2011) 
highlighted differences in the release behaviour from 
these coated formulations when bicarbonate buffer 
was used to simulate the intestinal phase, instead of 
conventional phosphate buffer, suggesting the 
importance of physiological resemblance of the test 
medium to the GI fluids.  This is further supported 
by evidence from other studies (Goyanes et al., 2015; 
Merchant et al., 2014; Varum et al., 2014).  
Apart from ionic strength, buffering species and 
strength, other components of the gastrointestinal 
milieu have also proven to be important, leading to 
the development and constant improvement of 
fasted/fed state simulated gastric and intestinal 
fluids (Dressman et al., 1998; Jantratid et al., 2008; 
Khoshakhlagh et al., 2015; Klein, 2010; Soderlind et 
al., 2010; Vertzoni et al., 2005; Vertzoni et al., 2004). 
Soderlind et al. (2010) studied the solubility of a 
range of neutral compounds using fasted state 
simulated intestinal fluid (FaSSIF), FaSSIF-V2, pH 6.5 
phosphate buffer and human intestinal fluids and 
highlighted interesting differences in the solubility 
profiles, further emphasising the importance of 
physiological relevance of the media in dissolution 
testing.  
Table 1 provides a summary of natural-based 
polymeric formulations already commercialised or 
with potential use for gastroresistant applications.  
STARCH 
Starch is a carbohydrate composed of glucose units 
bonded by glycosidic bonds to form amylose and 
amylopectin (Fig. 2.) and is present in most plants as 
a source of energy. It is abundant in the human diet 
and it can be found in potatoes, wheat, corn and rice. 
Due to this, the investigation of starch and its role as 
an excipient has been popular, considering it is 
degradable and GRAS.  
 
Fig. 2. Chemical structure of amylose (A) with α(1,4) glycosidic 
bonds and amylopectin (B) with α(1,4) and α(1,6) glycosidic 
bonds, both constituents of starch. 
Similar to other natural polymers, starch was initially 
explored as a film-forming agent for food packaging 
(Arvanitoyannis et al., 1998).  Later,  starch  capsules  
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Table 1. Summary of gastroresistant formulations for nutraceutical applications.  
Material Product and 
formulation 
Description Reference 
1. CELLULOSE 
Hydroxypropyl 
methylcellulose 
(HPMC)+  
gellan gum 
DRCaps™*  
(Capsules) 
Claimed to provide protection for acid sensitive 
ingredients using a delayed-release mechanism. Prone to 
significant inter- and intra-subject variability in gastric 
emptying affecting its effectiveness. 
Marzorati et al. (2015) 
Ethylcellulose 
(EC) + sodium 
alginate (SA) 
Nutrateric®* coated 
tablets 
Comprises EC coating containing SA, which dissolves at 
intestinal pH and forms pores in the EC coatings, 
enabling drug release. Although coated tablets remain 
intact in 0.1M HCl (pH≤1.2) for 2 h, coatings are not 
robust to resist gastric conditions pH >2.0, possibly 
leading to premature drug release in the stomach. 
Czarnocka and 
Alhnan (2015), 
Merchant et al. (2009), 
Young et al. (2006)  
2. STARCH 
Maize starch EUDRAGUARD®* 
Natural  coated 
tablets or pellets 
Based on maize starch and claimed to provide taste-
masking proprieties and acid-resistance. However, no 
further information is available on coating composition 
and on mechanisms of gastroresistance achieved using 
maize starch. It is not clear if this is also a delayed release 
approach, as in DRCapsTM, or is a pH sensitive coating.  
Evonik (2015), Kuntz 
(2016) 
High amylose 
corn starch 
(HACS) 
Coated glass beads HACS is highly resilient to both gastric (0.1M, pH1.6, 2h) 
and neutral (pH 7.0. 0.1M phosphate buffer, 3h) 
conditions. However, it is shown to dissolve in a 
medium containing pancreatic amylases. 
Dimantov et al. (2004) 
3. SHELLAC 
Shellac  
succinate 
Cast films Chemically modified shellac, where esterification with 
succinic anhydride and manipulation of annealing time 
allows the tailoring of the polymer’s dissolution pH. 
However, due to chemical modification, it potentially 
loses its GRAS status. 
Limmatvapirat et al. 
(2008) 
Shellac + inulin Coated tablets Coating resisted 0.1M HCl for 2 h, yet drug release was 
initiated when in phosphate buffer pH 7.4. Shellac 
provides the enteric resistance, while inulin purports to 
retard the drug release until the formulation reaches the 
colon. 
Ravi et al. (2008) 
Shellac +  
sodium alginate 
Protect™ Enteric* 
coated tablets 
Claimed to remain intact in 0.1M HCl for 2h, while 
disintegrating at pH 6.8 (phosphate buffer). However, in 
a recent study by Czarnocka and Alhnan (2015), a slower 
release rate was observed after the acid stage when 
transferred to pH 6.8 phosphate buffer (<50% release in 
4h) than in pH 7.4 phosphate buffer (80% release in 2h). 
Fraser and Young 
(2010), Czarnocka and 
Alhnan (2015) 
4. ZEIN 
Zein + PEG-400 
or glycerol 
Coated tablets While both organic and aqueous solutions resisted 2h at 
pH=1.2 for 2h, different lag times for drug release were 
observed when tested in pH 6.8 phosphate buffer. PEG-
400 and glycerol were shown to influence the drug release, 
with PEG 400 formulation having a lower water uptake 
than glycerol, thus causing a more delayed onset of 
release. 
Li et al. (2010) 
Carboxymethyl 
zein 
Tablet matrix Authors claim that with carboxymethyl modification, zein 
becomes soluble at pH 4.5, thus, dissolving at the pH of 
the small intestine, yet being resistant to fasted gastric pH. 
However, due to chemical modification it potentially loses 
its GRAS status. 
Yin et al. (2015) 
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Table 1 (continued).  Summary of natural-based polymeric formulations for gastroresistant applications.  
5. ALGINATE 
Sodium  
alginate + 
pectin 
Probiotic pearls™* 
(coated pellets) 
Triple-layered beads containing a core of probiotics in an oil 
suspension. It is claimed that the outer layer of sodium 
alginate and pectin offers the gastric protection, creating a 
gel layer under acidic conditions for 2 h, which is then 
expected to dissolve in the distal gut, hence releasing the 
probiotics. Due to the delayed release in intestine, it is not 
suitable for conventional gastroresistant applications 
however, it may be suitable for colon targeting. 
Nature’s Way 
Products (2011 a,b) 
Sodium  
alginate + 
chitosan 
Microparticles Probiotic containing microcapsules claimed to resist acidic 
conditions from pH 1.0 to 4.0 (HCl with 0.85% NaCl) for up 
to 8 h and subsequently released probiotic when tested in 
intestinal buffer containing 0.3% bile salts. It was reported 
that the probiotic viability was maintained throughout the 
test conditions. 
Wu et al. (2016) 
6. OTHERS  
Soy hydrogel Tablet matrix Tablets composed of lyophilised soy hydrogel, containing 
riboflavin, were shown to resist 0.1M HCl (pH 1.2) for 30 
min. When in pH 7.5 phosphate buffer, 50% of the riboflavin 
was released in 2h with complete release in 5h. Shorter 
testing duration in acidic conditions and slower and delayed 
release in the small intestine could be a concern. 
Maltais et al. (2010) 
Whey protein 
+ gum arabic 
Coated 
microcapsules 
Microcapsules containing hydrolase enzyme as a 
nutraceutical agent, resisted simulated gastric conditions 
(both in fed and fasted state, pH 4.5 and 2.0, respectively) for 
15 min. The enzyme was then shown to be fully active when 
at pH 7.0 (phosphate buffer). Nevertheless, the reduced 
testing duration  (only 15 min) in the gastric conditions is a 
serious limitation of this study, and it is not known if the 
encapsulated enzyme will remain stable under acidic 
conditions for longer than 15 min. 
Lambert et al. (2008) 
Marine 
sponge  
collagen 
Spongicol®* (coated 
tablets) 
Tablets coated with 12.9mg/cm2 complied with the Ph. Eur. 
specifications for delayed-release tablets with no drug 
release for 2h in 0.1M HCl, yet disintegrating within 10min 
in pH 6.8 phosphate buffer. This system is currently used in 
a nutraceutical formulation for ulcerative colitis. 
KliniPharm (2015) 
* commercialised products for nutraceutical use.
were developed and studied for their physical 
characteristics and their enteric targeting ability 
(Vilivalam et al., 2000). These capsules had similar 
characteristics to traditional gelatine capsules, with 
notable advantages in some cases. In terms of 
gastrointestinal drug delivery, starch has been 
mainly explored for colonic targeting (Kotla et al., 
2014; Norman, 2011). High-amylose starch is highly 
resilient to gastric conditions (pH 1.6, 0.1M HCl, 2 h) 
and also at neutral pH (pH 7.0, phosphate buffer 0.1 
M, 3 h), however when pancreatic enzymes are 
present, amylose is enzymatically digested, causing 
the disintegration of the dosage form (Dimantov et 
al., 2004). Carboxymethyl high amylose starch (CM-
HAS) has been used to produce oral vaccines for the 
delivery of F4 fimbriae to the colon and also as a 
complex with lecithin for a mesalazine-based colonic 
delivery system (Mihaela Friciu et al., 2013). 
Recently, a starch-based aqueous coating has been 
commercialized by Evonik Industries under the 
brand name of Eudraguard® Natural (Evonik, 2015). 
This coating is a GRAS substance and has been 
licensed to be used for nutraceutical formulations in 
the United States and in Europe (Hauschildt, 2016).It 
is claimed that this coating provides taste-masking 
and acid-resistant properties (Kuntz, 2016), however 
some information such as the type of starch and other 
composition of the coating system is not disclosed. 
SHELLAC 
Shellac is a resin secreted by the lac bug (Kerria lacca) 
and has been used as a protective layer for wood, 
leather or paper, insulating material (Azouka et al., 
1993), as a colorant, food glaze or acting as a sanding 
sealant, odour-blocker or as a high-gloss varnish 
(Baldwin et al., 1994). 
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Besides these, shellac was also used in the 
pharmaceutical industry as a sealant, glaze and in 
particular, in sugar coating. Due to its acidic 
properties, shellac also offers applications in 
developing gastroresistant products. There have 
been several reports describing various preparations 
of shellac-based films for enteric coatings however, 
due to several reported disadvantages, shellac has 
decreased in popularity as a material for acid 
protection. Problems such as its tackiness (Goorley 
and Lee, 1938) or changes in the dissolution profile of 
shellac-coated formulations caused by ageing 
(crosslinking and esterification) caused the decline of 
this material for enteric coating purposes (Agyilirah 
and Banker, 1991). Moreover, despite reports 
suggesting shellac’s resistance to the stomach’s acidic 
conditions, problems were reported when shellac 
was subject to the weakly-acidic conditions found 
during the ingestion of food. These caused the 
coating to dissolve prematurely, hence the loss of 
gastroresistance. Interest in shellac has resurfaced 
recently, with research being carried out regarding 
modifications of shellac to improve its quality as a 
gastroresistant material. Limmatv-apirat et al. (2008) 
developed a modified form of shellac (shellac 
succinate) in an attempt to improve its solubility in 
the small intestine. The unmodified shellac presented 
good gastric resistance in the fasted state, however it 
is not readily soluble at the small intestinal pH 
(Limmatvapirat et al., 2008; Ravi et al., 2008). The 
authors suggest that esterification with succinic 
anhydride, and the change in annealing time, made 
it possible to control the pH at which the polymer 
dissolves. Different annealing times influence the 
acid value of shellac (measure of free acid content), 
thus modifying the number of available carboxylic 
acids and consequently altering its solubility to occur 
at lower pH values. Moreover, Signorino and 
colleagues (Signorino, 2003; Signorino et al., 2010) 
found that formulations containing up to 60% of 
shellac would allow the tailoring of the pH at which 
the coating dissolves (ranging from 6.8 to above 7.4). 
This was achieved using different grades and types 
of shellac, bearing different acid numbers, and 
therefore controlling the release of the active 
ingredient. Also, Ravi et al. (2008) developed an 
enteric coating using shellac, and showed that the 
coating integrity was maintained when using 0.1M 
HCl for 2 h, yet drug release was initiated when the 
medium was changed to phosphate buffer pH 7.4. 
This particular formulation was designed with two 
different coatings, a shellac outer coating and an 
inulin-based inner coating. The shellac coating 
provides the ability to withstand the acidity of the 
stomach, whereas the inulin coating is present to 
retard drug release until it reaches the colon. These 
results may, however, not reflect the biological pH 
changes across the gastrointestinal tract. The authors 
reported that phosphate buffer (pH 7.4) was used to 
mimic conditions in the small intestine. Firstly, the 
USP test to mimic small intestinal conditions refers to 
pH 6.8, not 7.4. Moreover, as shown by Liu et al. 
(2011), the use of phosphate buffer as a release 
medium is not the most representative procedure to 
assess the release of enteric coated solid dosage 
forms, with bicarbonate buffer yielding more 
realistic results. 
Recently, Encap Drug Delivery, a division of 
Capsugel®, has developed a commercial shellac-
based coating formulation, described as containing 
GRAS materials and suitable for the delivery of 
pharmaceuticals and nutraceuticals (Fraser and 
Young, 2010; Young, 2006). This formulation has  
been shown to be resistant to the acidic pH of the 
stomach (0.1M HCl, 2h), using different coating 
thicknesses, yet disintegrating when in more neutral 
pH values (pH 6.8, phosphate buffer).  
Moreover, a combination of shellac and alginate was 
recently commercialised by Sensient 
Pharmaceuticals under the name of Protect™ Enteric 
(Sensient®, 2014). Czarnocka and Alhnan (2015) 
compared its performance with Nutrateric® 
(ethylcellulose films with alginate as pore-former) 
using theophylline tablets. Nutrateric® (6.5% and 7% 
weight gain) and Protect™ Enteric (2.75% and 3% 
weight gain) resisted the acid stage (0.1 M HCl for 2 
h). However, the shellac-containing product had a 
slower release rate in pH 6.8 phosphate buffer (less 
than 50% in 4 h) when using 2.75 and 3% coating 
level, whereas formulations coated with Nutrateric® 
released 80% of the drug in 65 or  90 min for 6.5% and 
7% coating weight gains respectively. Moreover, 
when tested in phosphate buffer pH 7.4, Protect™ 
Enteric formulations had a faster drug release, 
reaching 80% of the release in 2 h. This may indicate 
a possible use of this coating system for colonic 
delivery. The authors also studied the resistance of 
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the enteric coating at elevated stomach pH (pH 2.0, 
3.0 and 4.0), and where Nutrateric® failed, with 
dissolution times of 70 min (pH 2.0), 30 min (pH 3.0) 
and 55 min (pH 4.0),  Protect™ Enteric managed to 
fully retard drug release at all the pH values tested. 
Additionally, pH 7.4 Krebs bicarbonate buffer was 
used as a release medium. Nutrateric® formulations 
demonstrated similar release profiles in bicarbonate 
buffer (at pH 7.4) to those obtained in phosphate 
buffer (at pH 6.8), however, Protect™ Enteric 
formulations experienced a significant decrease in 
the release rate, exhibiting only < 20% drug release 
after 4 h in bicarbonate buffer. Although the authors 
do not present an explanation for these differences, 
this can be attributed to the polymers used in both 
drug delivery systems. Even though both systems 
have embedded alginates to act as pore-formers in 
response to pH changes, drug release from Protect 
films is mediated by the ionisation of both shellac 
and alginate, whereas in Nutrateric there is reliance 
on an alginate-only based pore-forming mechanism. 
It has previously been reported that drug release 
from ionisable polymeric films in phosphate buffer is 
faster than physiological bicarbonate buffers mainly 
due to the differences in ionic strength and buffer 
capacity (Fadda et al., 2009; Liu et al., 2011). 
Therefore, it is reasonable to expect a higher rate of 
release from Protect formulations when tested in 
phosphate buffer than in bicarbonate, presuming 
most of the drug release in phosphate buffer is 
attributed to the ionisation of shellac whereas drug 
release in bicarbonate may be attributed to its pore-
forming effect. This study also reiterates the 
importance of the physiological relevance of the 
release medium. 
As discussed previously, and as shown by Liu et al. 
(2011) and Czarnocka and Alhnan (2015), phosphate 
buffer may not indeed be the most suitable medium 
to mimic intestinal conditions, often generating 
misleading results. Although the results by 
Limmatvapirat et al. (2008), Fraser and Young (2010), 
Ravi et al. (2008) and Young (2006) using shellac as a 
possible enteric coating are promising, these may be 
different when a different media simulating 
intestinal conditions is used. Studies using 
bicarbonate buffer or other simulated intestinal 
fluids would thus provide a more comprehensive 
drug release profile.  
ZEIN  
Zein belongs to the family of alcohol-soluble proteins 
extracted from corn. Based on solubility and amino 
acid sequence, zein can be divided into four classes: 
α-zein (19 and 22 kDa), β-zein (14 kDa), γ-zein (16 
and 27 kDa) and δ-zein (10 kDa) (Esen, 1987; 
Thompson and Larkins, 1989). Fig. 3 shows the 
amino acid sequence of α-zein (22kDa), with the nine 
repeat sequences aligned to show the greatest 
number of identities between sequences. Each repeat 
sequence contains a glutamine (Glu – Q) rich end, 
represented by the black line connecting each α-helix. 
This structural arrangement creates rectangular “tri-
blocks”, with non-polar amino acids in the 
hydrophobic core and Glu-rich loops forming two 
hydrophilic edges (Auke de et al., 2014). Owing to its 
unique amino-acid composition, zein has a 
distinctive solubility profile, with its primary 
solvents being glycols, glycol-ethers, amino-alcohols, 
nitro-alcohols acids, amides, and amines (Lawton, 
2002). In terms of binary solutions, zein is soluble in 
water combined with a lower aliphatic alcohol 
(methanol, ethanol, isopropanol or butanol), acetone 
or dioxane. Moreover, a study by Li and colleagues 
described the mechanism of dissolution of α-zein in 
aqueous ethanol and acetic acid (Li et al., 2012) and 
revealed that acetic acid is a better solvent for zein 
than aqueous ethanol. Zein is widely used in the food 
industry as a coating for candies, nuts and fruits. 
Being labelled in the US as “confectioner’s glaze”, it 
is found as an ingredient of various food products, 
such as the caramel sweets, “sugar babies”. Zein has 
also been used to form edible films exhibiting 
antioxidant, antimicrobial or simple barrier 
properties for food packaging (Cheng et al., 2015; 
Escamilla-García et al., 2013; Gezer et al., 2015; 
Güçbilmez et al., 2007; Liang et al., 2015; Ünalan et 
al., 2013). 
The first reported use of zein as a coating material for 
tablets dates back to 1956 by Winters and Deardorff. 
They demonstrated that zein could be used as a 
coating to improve resistance against abrasion, 
humidity and heat compared to sugar-coated tablets. 
Moreover, zein has also been used as a coating to 
produce modified release formulations. For example, 
using a dry-coating technique, Guo and  Shi  (2009)  
prepared  sustained-release  tablets coated with zein  
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Fig. 3. Structural representation of α-zein (22kDa). Amino acid sequence, with the nine repeat sequences forming α-helixes linked by 
Glutamine (Q) rich loops, creating rectangular “tri-blocks”, with non-polar amino acids in the hydrophobic core and Q-rich loops forming 
two hydrophilic edges. Adapted from (Argos et al., 1982; Auke de et al., 2014). 
and microcrystalline cellulose (MCC) or starch. 
Further work on zein films by the same group 
evaluated the effects of plasticisers, pH and 
electrolytes on film formation and physical stability 
(Guo et al., 2008). More recently, zein was used to 
coat selenite-loaded chitosan nanoparticles (Luo et 
al., 2010).  
Zein has also been a candidate of interest for enteric 
coatings, due to its poor solubility at low pH, and 
good solubility in intestinal conditions. Reports 
concerning the application of zein in enteric coatings 
are somewhat contradictory (Li et al., 2010; 
O'Donnell et al., 1997).  
An early report of zein for enteric applications from 
Kanig and Goodman (1962) reported that zein films, 
containing oleic acid as a plasticiser, were insoluble 
in USP simulated gastric media (pH 1.2) for 2 hours, 
but completely dissolved in intestinal conditions (pH 
6.8 phosphate buffer USP) within a few seconds. A 
different formulation containing zein was developed 
by O'Donnell et al. (1997). The paracetamol tablets 
were coated with zein dispersions containing 
propylene glycol as a plasticiser and methyl or 
propyl parabens as preservatives. Compared to the 
zein films reported by Kanig and Goodman (1962), 
formulations prepared by O’Donnell et al., had a 
higher (~2x) water content. A faster release rate of 
paracetamol was observed from these coated 
formulations in acidic medium than in the intestinal 
buffer. It is not clear as to why the drug release in 
acidic medium was faster, however the authors 
concluded that this was due to the zein coating 
applied to the tablets. Li et al. (2010) further studied 
organic solutions and aqueous dispersions of zein for 
coating purposes and also investigated the influence 
of plasticisers (PEG400 and glycerol). The 
formulations were tested in acidic conditions (0.1M 
HCl for 2 hours) followed by pH 6.8 phosphate 
buffer. All formulations have shown to resist the 
acidic conditions for the tested time. However, when 
these were transferred to pH 6.8 phosphate buffer, 
the lag time for aqueous formulations was 
significantly higher than the organic formulations. 
80% drug release was noted at 12h and 30h hours for 
aqueous formulation with glycerol and PEG400 
respectively. Apart from the difference between 
organic and aqueous formulations, this study also 
showed that the choice of plasticiser greatly 
influences drug release from these dosage forms. 
Even though the preparation method for the aqueous 
formulations was similar to that of O'Donnell et al. 
(1997), the results are contradictory. A reason for 
these may be pH-dependant solubility of the drug 
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but also to the fact that zein can be supplied with 
different grades, with the possibility of significant 
variability existing between suppliers, causing 
variations in the obtained results. Nevertheless, the 
results by Li et al. (2010) are in accordance with the 
results by Kanig and Goodman (1962).  
Stability of aqueous dispersions of zein at different 
pH values was studied for 30 days by Guo et al. 
(2008). Dispersions in which pH was adjusted to 
between 2.5 and 4.5 were shown to be more stable. 
Interestingly, phase separation was observed when 
the dispersion pH was adjusted above 4.5, which was 
attributed to the reduction in absolute zeta potential 
of the dispersion, causing particles to not repel each 
other, leading to agglomeration. This may also 
suggest that at pH 2.5-4.5, zein was ionised to some 
extent, which kept the dispersion stable under those 
conditions. Recently, Yin et al. (2015) proposed a 
modification of zein by carboxymethylation using 
sodium monochloro-acetate. With this modification, 
the authors suggest that the pH at which the polymer 
becomes soluble is changed from pH ~9 to around 
4.5, hence being resistant to fasted gastric pH, yet 
soluble at the pH of small intestine, and therefore 
producing a promising candidate for gastroresistant 
applications.  
CASEIN  
Milk proteins are a heterogeneous mixture of two 
main groups, casein and whey proteins (El-Zahar et 
al., 2004). This section focuses on the properties of 
casein, with whey proteins being explored in the 
following section in detail. Mainly four casein 
phosphoproteins exist in cow milk, α(S1 and S2)-, β- 
and κ-casein, in an approximate proportion of 4:1:4:1 
respectively, with a molecular weight of 19 to 25 kDa 
and an isoelectric point between 4.6 and 4.8 
(Elzoghby et al., 2011). Casein has been widely 
explored for a range of pharmaceutical applications, 
for example in producing hydrogels for drug 
delivery (Li et al., 2014; Song et al., 2010; Song et al., 
2009; Zhang et al., 2015), floating devices for 
gastroretentive formulations (Bulgarelli et al., 2000; 
Elzoghby et al., 2015; Mishra et al., 2008) and drug-
casein compacts to improve drug solubility (Gubbins 
et al., 2003; Millar and Corrigan, 1991, 1993). 
Moreover, several recent studies have reported 
casein-based nano-vehicles for oral delivery of folic 
acid (Penalva et al., 2015), anticancer agents (Shapira 
et al., 2010a; Shapira et al., 2012; Shapira et al., 2010b) 
and other compounds (Bachar et al., 2012; Esmaili et 
al., 2011; Luo et al., 2015). 
Additionally, this material was proposed as a 
potential coating agent for solid dosage forms. Abu 
Diak et al. (2007) studied the influence of different 
plasticisers on the formation of casein films as well as 
the influence of different coating levels (5-15% 
weight gain) and different heat treatment 
temperatures (60-100°C) for 24 h. The coated tablets 
that had greater resistance to gastric conditions (15% 
coating level, 100°C heat treatment and 20% oleic 
acid as plasticiser), released only 2.6% of the drug 
(diltiazem HCl) after 2 h in 0.1 N HCl (pH 1.2), 
however, after 2 h in phosphate buffer pH 6.8, only 
approximately 20% of the drug was released. 
Alternatively, when decreasing the heat treatment 
temperature to 60°C, the release in acidic conditions 
slightly increased to 9.4% however after 2 h in nearly 
neutral conditions, the release increased to around 
80%. A high percentage of coating (15% weight gain) 
and plasticiser (20% oleic acid) provided more 
effective gastric protection. The curing temperature 
clearly influences the resistance of the coating to both 
acidic and alkaline conditions. The temperature 
range tested and the long curing time (24 h) may 
however pose as a challenge when trying to employ 
this material with particularly heat labile drugs.  
More recently, Huang et al. (2015) designed a casein-
coated drug delivery system composed of 
doxorubicin-loaded iron oxide nanoparticles, pre-
coated with poly(maleic acid), which were then over-
coated with casein. The coating with casein provided 
an additional barrier, decreasing the amount of drug 
released in simulated gastric fluids (pH 2.0 
containing 1.0 mg/mL pepsin, 2h) from 70% to 40%. 
Also, when the system was tested at different pH 
values, the drug release decreased with increasing 
pH. However, when trypsin was added to the release 
medium, the released rate increased. This confirms 
the importance of using release media, not only with 
the right pH, but also containing relevant enzymes in 
the gastric and intestinal phases for particular 
applications.  
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WHEY PROTEIN 
As mentioned in previous section, whey proteins are 
one of the main groups of proteins present in milk, 
along with casein. Whey proteins in milk are mostly 
β-lactoglobulin, α-lactalbumin and serum albumin 
(El-Zahar et al., 2004). Bovine β-lactoglobulin is 
highly stable at acidic pH, resisting denaturation at 
pH values as low as 1, but is easily denatured at 
alkaline pHs (above pH 9) (Taulier and Chalikian, 
2001). Studies by Fu et al. (2002) and Takagi et al. 
(2003) demonstrated that native β-lactoglobulin is 
almost entirely resistant to pepsin degradation at low 
pH and also that the protein remained intact in 
simulated gastric fluids (3.2 mg/mL pepsin in 0.03 M 
NaCl, pH adjusted to 1.2 with HCl). β-lactoglobulin 
represents around 60% of the whey proteins in 
bovine milk (Nicolai et al., 2011), and consequently is 
also present in high amounts in whey protein isolate 
(WPI). Thus, WPI could be an interesting material to 
develop gastroresistant formulations. Lambert et al. 
(2008) used whey protein together with gum arabic 
to produce microcapsules containing the model 
enzyme bile salt hydrolase for targeted delivery to 
the small intestine. Their study found that these 
microencapsulates resist simulated gastric 
conditions (fed state: pH 4.5, 5 mM acetate buffer, 
ionic strength 70 mM, 15 min; fasted state: pH 2, 5 
mM phosphate buffer, ionic strength 70 mM, 15 min) 
and that the enzyme  remains fully active in intestinal 
conditions (50 mM phosphate buffer, pH 7; ionic 
strength, 111 mM). These microencapsulates were 
formulated using 350-500 µm microcrystalline 
cellulose spheres, which were sprayed sequentially 
with the model enzyme, whey protein and then gum 
Arabic. It appears that the gelling of the gum Arabic 
in acidic environments and the acid resistance of the 
whey protein protected the enzyme from acid (at 
least during the duration of the study). However, at 
higher intestinal pH, the coating porosity increases 
due to degradation of whey protein layer, enabling 
the enzyme release. Even though these results appear 
encouraging, again, the use of appropriate simulated 
conditions is of great importance. Despite the fact 
that the authors did test their sample in the fasted 
and fed state, the time in the simulated gastric fluid 
was much reduced (15 min), compared to the USP 
recommended test (2 h). Literature on the use of WPI 
for enteric coatings is still scarce and is a possible 
avenue for further development. 
SOY PROTEIN 
Soy protein is extracted from soy beans and contains 
high amounts of aspartic acid (ASP) and glutamic 
acid (GLU) (Asif and Acharya, 2013). Since these two 
amino acids contain an acidic side chain (Fig. 4.) with 
pKas of 3.71 (ASP) and 4.15 (GLU), they are potential 
candidates for enteric coatings. However, soy 
protein, or soy protein isolate (SPI), as is 
commercially available, has not yet been explored for 
this application.  
Incorporating soy in a tablet matrix, Maltais et al. 
(2010) developed a riboflavin-loaded lyophilised soy 
hydrogel. The lyophilised powder was then 
compressed into tablets and then tested for 30 min in 
simulated gastric fluid (pH1.2, with and without 3.2 
g/L of pepsin) followed by 6 h in simulated intestinal 
conditions (phosphate buffer pH 7.5, with and 
without 10.0g/L of pancreatin). 
 
Fig. 4. Structure of aspartic acid (A) and glutamic acid (B). 
The tablet was shown to withstand acidic conditions, 
with negligible release of the active substance (less 
than 3%), with 50% of the drug released after 2h in 
intestinal conditions (with pancreatin), and nearly 
100% after 5 h in these conditions. The acid stage in 
this work only lasted 30 min, as opposed to the 
standard 2 hours compendial acid challenge test. 
However, riboflavin release was also assessed 
separately in simulated gastric fluids (same 
composition as before) for 24 h, exhibiting about 5% 
drug release after 2 h, suggesting soy may be a 
promising candidate for gastro-resistant 
applications.  
Nonetheless, there are not many studies employing 
soy protein in enteric formulations, hence the 
evidence to support such an application is weak and 
warrants further research.  
ALGINATE 
Alginate is an anionic polysaccharide composed of β-
D-mannuronate and α-L-guluronate (Fig. 5) present 
in cell walls of brown algae (Lee and Mooney, 2012).  
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Fig. 5 – Representation of alginate structure, with m repetitions 
of α-L-guluronate and n repetitions of β-D-mannuronate, linked 
by β(1-4) bonds. 
Alginate has been used to provide enteric protection 
using triple-layered granules containing probiotics. 
Probiotic Pearls™ are an example of commercially 
available, triple-layered beads containing different 
probiotics (such as Lactobacillus and Bifidus spp), 
which purport to use this technology, where the 
outer layer contains a blend of alginate and pectin to 
withstand the acidic conditions of the stomach 
(Nature's Way Products, 2011a,b), however, several 
patents have been submitted using similar 
technology (Penhasi, 2012; Zorea, 2011). The outer 
layer forms an acidic gel under gastric conditions, 
which is expected to subsequently dissolve in the 
distal gut, thus releasing the encapsulated probiotics. 
In another study, alginate/chitosan microparticles 
containing probiotic cells (Bacillus licheniformis) were 
developed by Wu et al. (2016); these were able to 
maintain cell viability under acidic conditions (pH 
1.0 to pH 4.0) for up to 8 h. However, such systems 
(Penhasi, 2012; Wu et al., 2016; Zorea, 2011) may not 
work for conventional gastroresistant applications 
which require the active ingredient to be released 
higher in the proximal small intestine. These 
systems, in contrast, are rather more suitable for 
further delayed release applications, for instance 
colonic targeting. 
OTHERS 
In addition to the above systems, a few other natural 
polymers have also been studied for gastroresistant 
applications, such as marine sponge collagen 
(Nicklas et al., 2009). This material resisted the 
compendial acid challenge (2h in 0.1M HCl), 
contrasting with type I collagen, which displays 
quick degradation into tropocollagen in acidic media 
(Heinemann et al., 2007). Tablets coated with 
12.9mg/cm2 complied with the Ph. Eur. 
specifications for delayed-release tablets, showing no 
disintegration or degradation for 2h in 0.1M HCl, yet 
disintegrating within 10min when in pH6.8 
phosphate buffer. This system is currently being 
used in a nutraceutical formulation for ulcerative 
colitis under the name Spongicol® (KliniPharm, 
2015). 
CONCLUSIONS 
Studies on naturally occurring materials with 
potential gastroresistant properties that can be 
employed for nutraceutical products are quite scarce. 
Even though some materials have been developed 
using polymers from nature, more accurate and 
better designed dissolution studies are needed to 
understand the dissolution profile of these 
substances. 
Recently several natural materials like 
pectin/alginate (Nature's Way Products 2011a), 
shellac (Fraser and Young, 2010) and alginate 
(Colorcon®, 2015) have been employed. However 
their gastroresistant properties are not comparable to 
those employed in pharmaceutical products and lack 
robustness over a wider spectrum of gastric pH 
(Czarnocka and Alhnan, 2015; Merchant et al., 2009), 
and residence time accounting for inter- and intra-
subject variability (time of the day, type and size of 
meal, demographics etc.). Therefore, there is still a 
need for a better solutions for the fast-growing 
nutraceutical market, and further research in this 
area is needed. 
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